Comparison of the efficacy of aflibercept and ranibizumab in myopic subretinal neovascular membranes. COAST.UA research (report №1)

Abstract

The prevalence of pathological myopia is 1-3% in the adult population, of which 5-11% of cases develop subretinal neovascular membranes. The aim of this study was to compare the effectiveness of ranibizumab and aflibercept in the treatment of patients with subretinal neovascular membrane in myopia. As a result of the study, it was found that the use of ranibizumab and aflibercept similarly increased visual acuity in patients with subretinal neovascular membrane in myopia, without a significant difference in the number of intravitreal injections performed at a follow-up period of 12 months. In addition, ranibizumab and aflibercept significantly reduce the central thickness of the retina.